Bicycle Therapeutics plc (BCYC)
NASDAQ: BCYC · Real-Time Price · USD
3.620
-0.040 (-1.09%)
At close: Nov 2, 2026, 4:00 PM EST
3.600
-0.020 (-0.55%)
After-hours: Nov 2, 2026, 7:30 PM EST

Bicycle Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
83.5372.5935.2826.9814.4611.7
Revenue Growth
194.75%105.77%30.76%86.52%23.65%12.58%
Cost of Revenue
164.05229.08164.86147.6581.6144.88
Gross Profit
-80.53-156.5-129.59-120.68-67.15-33.18
Selling, General & Admin
73.586.3779.1969.2749.5132.44
Operating Expenses
73.586.3779.1969.2749.5132.44
Operating Income
-154.03-242.87-208.77-189.95-116.65-65.62
Interest Expense
-0.19-0.21-1.73-3.26-3.34-2.98
Interest & Investment Income
19.3328.4634.28145.760.12
EBT Excluding Unusual Items
-134.89-214.61-176.22-179.21-114.24-68.48
Other Unusual Items
-4.2-4.22.42---
Pretax Income
-139.09-218.81-173.8-179.21-114.24-68.48
Income Tax Expense
2.70.15-4.771.46-1.52-1.66
Net Income
-141.79-218.96-169.03-180.66-112.72-66.82
Net Income to Common
-141.79-218.96-169.03-180.66-112.72-66.82
Net Income Growth
------
Shares Outstanding (Basic)
706958363025
Shares Outstanding (Diluted)
706958363025
Shares Change
0.70%19.02%63.54%20.00%18.35%30.90%
EPS (Basic)
-2.03-3.16-2.90-5.08-3.80-2.67
EPS (Diluted)
-2.03-3.16-2.90-5.08-3.80-2.67
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-177.04-252.03-165.96-63.56-105.1-16.82
Free Cash Flow Per Share
-2.54-3.64-2.85-1.79-3.54-0.67
Gross Margin
-96.41%-215.60%----283.69%
Operating Margin
-184.40%-334.59%-591.84%-704.13%-806.56%-560.98%
Profit Margin
-169.75%-301.66%-479.18%-669.72%-779.35%-571.25%
Free Cash Flow Margin
-211.95%-347.21%-470.47%-235.61%-726.67%-143.83%
EBITDA
-149.42-236.44-201.6-183.4-112.96-64.21
EBITDA Margin
-178.89%-----
D&A For EBITDA
4.616.427.176.553.691.41
EBIT
-154.03-242.87-208.77-189.95-116.65-65.62
EBIT Margin
-184.40%-----
SEC Filings: 10-K · 10-Q